Organogenesis
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Organogenesis sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Organogenesis: 20 sponsored US clinical trials, 2 recruiting.
Organogenesis sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 14 completed. 8 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Venous Ulcer, with 3 trials.
Top-decile sponsor footprint
Organogenesis ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 18 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)
NCT07510412
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
NCT06618612
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
NCT06000410
Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
NCT04636229
PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.
NCT03502824
Affinity Prospective Diabetic Foot Trial Crossover Group
NCT03205436
The RESPOND Registry
NCT03286452
Prospective PuraPly™ AM Case Series Study
NCT03070925
PuraPly™ Antimicrobial Wound Matrix and Wound Management
NCT03070938
Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers
NCT02880592
Safety Study of Gintuit™ in Subjects Requiring Socket Grafting
NCT01929954
A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
NCT01327937
Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
NCT00909870
A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage
NCT00679081
A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
NCT00587587
Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)
NCT00587223
Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration
NCT00587834
A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva
NCT01547962
Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers
NCT01181453
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
NCT01181440
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
Where Organogenesis enrollment is open (later-stage tilt)
2 recruiting of 20 indexed (10% open); 14 completed (70%).
Phase mix: 8 late (III/IV) vs 3 early (I/II) (later-stage heavy).
Top condition: Venous Ulcer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Organogenesis: open-pipeline peers nationwide
Peers matched on 20 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Organogenesis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
- Ascension Health · 10% recruiting · 10 trials
Related
What to do with this Organogenesis page
20 registered trials is a research-attention snapshot, not an endorsement of Organogenesis or any single study.
- 2 of Organogenesis's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Venous Ulcer is the condition Organogenesis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Venous Ulcer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Organogenesis pipeline card: 20 registered trials from official public datasets.Report a data error.